Market cap ¥1.83TNext earnings 2026-11-10Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionOlympus Corporation (7733.T)
Fair value
Not available
ACCE price target
¥1884
Rating
Not rated
Horizon
12 months
ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ¥1719 at the close on 23 Oct 2026, 08:30 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
64
out of 100
P/E
27.5x
forward 13.7x
1-year return
-12.2%
Dividend yield
1.78%
Olympus Corporation in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Olympus makes endoscopes and the imaging, visualisation and surgical systems that go with them, with the gastrointestinal endoscope franchise being the core of the business. Its moat rests on an installed base of scopes and processors that hospitals retrain staff on and rarely switch away from, which supports the 64.7% gross margin. The near-term driver is the recovery in procedure volumes and the Japan-to-global mix shift in its endoscopy and surgical lines, with revenue growing 16.4%. The stock trades on a trailing P/E of 27.8 but a forward P/E of 13.4, a gap that implies earnings are expected to step up sharply from here, so the case depends on whether that margin expansion arrives. Operating margin of 12.5% and ROE of 10.6% are the figures to check against that claim before going further.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
moderate
Quarterly revenue dip
Revenue fell 18.6% QoQ even though it grew 16.4% YoY, so the latest quarter is weaker than the year-ago trend suggests and may not hold.
moderate
Earnings growth flattered
Earnings rose 122.6% YoY from a weak base, and the EPS beat was 84.7%. Five-year revenue CAGR is only 4.6%, so the spike may not be durable.
moderate
Rich trailing multiple
Trailing P/E is 27.5 against a forward P/E of 13.4, and the stock trades 8.8% below the ACCE price target of ¥1884.00. The gap rests heavily on forecasts.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-10-22 · prices to Oct 23, 2026
Why it could do well
Revenue grew 16.4% year over year, well above the company's 4.6% average annual pace over five years.
Forward earnings multiple of 13.4x is roughly half the trailing 27.5x, suggesting earnings are expected to rise sharply.
Analysts' mean price target of JPY 2084.62 sits 23.9% above the current share price, and the ACCE price target is ¥1884.00.
Why it could disappoint
Net margin of 7.5% and return on equity of 10.6% are modest for a company asking investors to pay 27.5x trailing earnings.
The latest earnings beat of 84.7% followed a weak base, so the surge may not repeat and the trailing multiple looks expensive.
Free cash flow of JPY 17.3B against a 0.43 debt to equity ratio leaves less cushion if growth slows from its recent pace.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where 7733.T's valuation models land
Price
¥1719.00
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.